ACXP
Acurx Pharmaceuticals Inc

1,961
Mkt Cap
$8.34M
Volume
30,683.00
52W High
$29.40
52W Low
$3.80
PE Ratio
-0.47
ACXP Fundamentals
Price
$4.00
Prev Close
$4.00
Open
$4.09
50D MA
$5.28
Beta
0.80
Avg. Volume
1.45M
EPS (Annual)
-$17.45
P/B
1.98
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals Health~Holland Awards Another Innovative Research...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update PR Newswire STATEN...
PR Newswire·8d ago
News Placeholder
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens Acurx Announces Publication in the Nature...
PR Newswire·10d ago
News Placeholder
Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference Acurx Announces...
PR Newswire·23d ago
News Placeholder
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial...
PR Newswire·24d ago
News Placeholder
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors PR Newswire STATEN ISLAND, N.Y., Oct...
PR Newswire·1mo ago
News Placeholder
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
Zacks·5mo ago
News Placeholder
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
chainwire·7mo ago
News Placeholder
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI Acurx Announces Publication of Positive...
PR Newswire·9mo ago
News Placeholder
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors PR Newswire STATEN ISLAND...
PR Newswire·9mo ago

Latest ACXP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.